Meningococcemia pathophysiology

Jump to navigation Jump to search

Meningococcemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Meningococcemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Treatment

Medical Therapy

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Meningococcemia pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Meningococcemia pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Meningococcemia pathophysiology

CDC on Meningococcemia pathophysiology

Meningococcemia pathophysiology in the news

Blogs on Meningococcemia pathophysiology

Directions to Hospitals Treating Meningococcemia

Risk calculators and risk factors for Meningococcemia pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Overview

Pathophysiology

  • Transmission through respiratory secretions from a nasopharyngeal carrier case-patient.
  • Shock is due to lipooligosaccharide which is a potent toxin. This toxin initiates release of inflammatory cytokines, reactive oxygen radicals, prostaglandins, arachidonic acid, complement activated products, platelet aggregating factor, and perhaps nitric oxide.

Molecular Biology

  • The polysaccharide capsule is the basis of the serogroup typing system.
  • 13 Serotypes are described based on capsular polysaccharide: A, B, C, D, X, Y, Z, E, W-135, H, I, K, and L.
  • Serogroup A usually with epidemics in less developed nations and an attack rate of as high as 500 cases per 100,000 population.
  • Serogroup B usually in developed nations with attack rate of 50-100 cases per 100,000 population.
  • Serogroup C usually in both developed and less developed populations and an attack rate of up to 500 per 100,000 population.

References


Template:WikiDoc Sources